Last reviewed 2026-04-20 · How we verify

Klamar (GUAIAPATE)

Phase 2 active Small molecule

Klamar (generic name: GUAIAPATE) is a guaiapate drug. It is currently in Phase 2 development.

Klamar (GUAIAPATE) is thought to work by interacting with a specific biological target to produce a therapeutic effect.

Klamar (GUAIAPATE) is a small molecule drug in the guaiapate class, but information on its target and mechanism of action is not available. Its commercial status and approved indications are also unknown. As a guaiapate, it is likely used to treat respiratory or gastrointestinal issues, but further research is needed to confirm its clinical applications. Klamar's safety profile, pharmacokinetics, and patent status are also unclear. Further investigation is required to fully understand this compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GUAIAPATE
Drug class	guaiapate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Klamar is a key that fits into one of those locks. When it binds to the lock, it triggers a response that helps to treat a particular condition. This is a simplified explanation of how Klamar might work, but the actual mechanism is likely more complex and involves specific biochemical interactions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Klamar CI brief — competitive landscape report
Klamar updates RSS · CI watch RSS

Frequently asked questions about Klamar

What is Klamar?

Klamar (GUAIAPATE) is a guaiapate drug.

How does Klamar work?

Klamar (GUAIAPATE) is thought to work by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Klamar?

GUAIAPATE is the generic (nonproprietary) name of Klamar.

What drug class is Klamar in?

Klamar belongs to the guaiapate class. See all guaiapate drugs at /class/guaiapate.

What development phase is Klamar in?

Klamar is in Phase 2.

Drug class: All guaiapate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing